Eptifibatide
GPIIb/IIIa antagonist for acute coronary syndrome. Cyclic heptapeptide inhibiting platelet aggregation, reducing ischemic complications in ACS and PCI procedures.
Eptifibatide, marketed under the brand name Integrilin, is a cyclic heptapeptide and the first FDA-approved platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonist derived from a natural source. Originally isolated from the venom of the pygmy rattlesnake (Sistrurus miliarius barbouri), eptifibatide was structurally optimized to become a potent, selective, and rapidly reversible inhibitor of platelet aggregation. It received FDA approval in 1998 and has since become a cornerstone therapy in interventional cardiology.
| Parameter | Specification |
| CAS | 188627-80-7 |
| Molecular Formula | C₃₅H₄₉N₁₁O₉S₂ |
| Molecular Weight | 831.96 g/mol |
| Category | Cardiovascular |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | Acute coronary syndrome, PCI, platelet aggregation inhibition |
| CAS | 188627-80-7 |
|---|---|
| Applications | Acute Coronary Syndrome, NSTEMI, Percutaneous Coronary Intervention |
Related products
-
Exenatide Acetate
CAS: 141732-76-5Applications: GLP-1, obesity management, Type 2 diabetes -
Tirzepatide
CAS: 2023788-19-2Applications: Advanced obesity, metabolic syndrome, Type 2 diabetes -
Abarelix
CAS: 183552-38-7Applications: Advanced Prostate Cancer, Hormone-dependent Tumors, Testosterone Suppression -
Pramlintide
CAS: 196078-30-5